Rossari Biotech Targets Debt-Free Status In Coming Months

Market snapshot: Rossari Biotech expects to transition into a debt-free company in the coming months, supported by consistent operational cash generation. The specialty chemicals producer has steadily pared down its total outstanding obligations while continuing capital investments through internal accruals.

Data Snapshot

• Net debt decreased to ₹221 crore as of September 2026, down from ₹281 crore in March 2026.
• Generated ₹131 crore in operating cash flows during the first half of FY27.
• Reported Q2 FY27 revenue of ₹697.6 crore (+19.0% YoY) and EBITDA of ₹87 crore (+20.9% YoY).

What's Changed

• Net debt reduced by ₹60 crore over six months, moving from ₹281 crore in March 2026 down to ₹221 crore by September 2026.
• Net working capital requirements improved to 86 days in September 2026 from 97 days in March 2026.

Key Takeaways

• Rossari Biotech's leverage reduction is backed by ₹131 crore in cash flows from operations in H1 FY27.
• Core operations deliver solid margin stability, with Q2 FY27 core B2B EBITDA margins reaching 14.1%.
• De-leveraging provides head-room for international expansion, including approved greenfield investments in Saudi Arabia.

SAHI Perspective

Rossari Biotech's guidance to achieve zero debt highlights financial discipline and cash flow conversion strength. By funding greenfield assets and debt paydowns simultaneously via operating cash, the balance sheet gains flexibility against macroeconomic cycles.

Market Implications

Eliminating interest expenses will directly benefit net earnings quality. Decreasing interest costs allows higher internal capital allocation towards expanding specialty performance chemical capacities and overseas ventures.

Trading Signals

Market Bias: Bullish

Strong de-leveraging trajectory supported by ₹131 crore H1 FY27 operating cash flow and a ₹60 crore net debt reduction since March 2026 provides a solid fundamental backstop.

Overweight: Specialty Chemicals

Trigger Factors:

• Formal announcement of full debt clearance in coming quarterly results
• Sustained quarterly EBITDA margin performance above 12.5%

Time Horizon: Near-term (0-3 months)

Industry Context

Specialty chemical manufacturers face raw material input cost volatility and export demand fluctuation. Maintaining a debt-free structure insulates manufacturers from borrowing cost surges while providing agile expansion capability.

Key Risks to Watch

• Raw material price volatility in ethylene oxide (EO) and related surfactant feedstocks.
• Global macroeconomic headwinds impacting export order volumes.

Recent Developments

In October 2026, Rossari Biotech's Board approved the lease of land in Saudi Arabia for a greenfield manufacturing facility under Rossari International, alongside commissioning one of India's largest EO storage units at its Unitop plant.

Closing Insight

A transition to zero debt positions Rossari Biotech to reinvest internal accruals into international facilities while insulating equity value from elevated interest rate environments.

High Performance Trading with SAHI.